 |
GTX Inc GTXI (news,
chart,
quote) - GTXI May volatility at 136 into data
GTXI, Biopharmaceutical Company, is recently down 26c to $17.08. Acapodene (prostate cancer treatment) in PIN Phase 3 data release is expected soon. GTXI is scheduled to report Q1 EPS |
|
